Matteo Cella1, Łukasz Okruszek2, Megan Lawrence3, Valerio Zarlenga3, Zhimin He3, Til Wykes3. 1. Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK. Electronic address: matteo.cella@kcl.ac.uk. 2. Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; Institute of Psychology, Polish Academy of Sciences, Warsaw, Poland. 3. Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.
Abstract
INTRODUCTION: Research suggests that people with schizophrenia have autonomic dysfunctions. These have been linked to functioning problems, symptoms and considered a risk factor for illness chronicity. The aim of this study is to introduce a new Mobile Health (mHealth) method using wearable technology to assessing autonomic activity in people's everyday life. We aim to evaluate the new method acceptability and characterise the association between schizophrenia illness features and autonomic abnormalities. METHOD: Thirty participants with schizophrenia and 25 controls were asked to wear a mHealth device measuring autonomic activity and movements during their normal everyday life. Measures of device use acceptability were collected from all participants. Participants with schizophrenia were also assessed for symptoms and functioning levels. Measures of heart rate variability (HRV), electrodermal activity (EDA) and movement were collected by the device and groups were compared. Correlation between physiological measures, functioning, symptoms and medication levels were assessed in people with schizophrenia. RESULTS: The mHealth device method proved to be acceptable and produced reliable measures of autonomic activity and behaviour. Compared to controls, people with schizophrenia showed lower levels of HRV, movement and functioning. In people with schizophrenia illness severity, particularly positive symptoms, was associated with parasympathetic deregulation. CONCLUSIONS: Autonomic abnormalities can be detected using wearable technology from people's everyday life. These are in line with previous research and support the notion that autonomic deregulation are relevant illness features for mental and physical health in schizophrenia. This method may be developed as a monitoring system for well-being and relapse prevention.
INTRODUCTION: Research suggests that people with schizophrenia have autonomic dysfunctions. These have been linked to functioning problems, symptoms and considered a risk factor for illness chronicity. The aim of this study is to introduce a new Mobile Health (mHealth) method using wearable technology to assessing autonomic activity in people's everyday life. We aim to evaluate the new method acceptability and characterise the association between schizophrenia illness features and autonomic abnormalities. METHOD: Thirty participants with schizophrenia and 25 controls were asked to wear a mHealth device measuring autonomic activity and movements during their normal everyday life. Measures of device use acceptability were collected from all participants. Participants with schizophrenia were also assessed for symptoms and functioning levels. Measures of heart rate variability (HRV), electrodermal activity (EDA) and movement were collected by the device and groups were compared. Correlation between physiological measures, functioning, symptoms and medication levels were assessed in people with schizophrenia. RESULTS: The mHealth device method proved to be acceptable and produced reliable measures of autonomic activity and behaviour. Compared to controls, people with schizophrenia showed lower levels of HRV, movement and functioning. In people with schizophrenia illness severity, particularly positive symptoms, was associated with parasympathetic deregulation. CONCLUSIONS:Autonomic abnormalities can be detected using wearable technology from people's everyday life. These are in line with previous research and support the notion that autonomic deregulation are relevant illness features for mental and physical health in schizophrenia. This method may be developed as a monitoring system for well-being and relapse prevention.
Authors: Noelle R Leonard; Bethany Casarjian; Richard R Fletcher; Cathleen Praia; Dawa Sherpa; Anna Kelemen; Sonali Rajan; Rasheeda Salaam; Charles M Cleland; Marya Viorst Gwadz Journal: JMIR Pediatr Parent Date: 2018-01-03
Authors: Jussi Seppälä; Ilaria De Vita; Maria Bulgheroni; Timo Jämsä; Jouko Miettunen; Matti Isohanni; Katya Rubinstein; Yoram Feldman; Eva Grasa; Iluminada Corripio; Jesus Berdun; Enrico D'Amico Journal: JMIR Ment Health Date: 2019-02-20
Authors: Neil Thomas; Josef J Bless; Ben Alderson-Day; Imogen H Bell; Matteo Cella; Tom Craig; Philippe Delespaul; Kenneth Hugdahl; Julien Laloyaux; Frank Larøi; Tania M Lincoln; Björn Schlier; Prabitha Urwyler; David van den Berg; Renaud Jardri Journal: Schizophr Bull Date: 2019-02-01 Impact factor: 9.306
Authors: Nicholas Meyer; Maximilian Kerz; Amos Folarin; Dan W Joyce; Richard Jackson; Chris Karr; Richard Dobson; James MacCabe Journal: JMIR Mhealth Uhealth Date: 2018-10-30 Impact factor: 4.773
Authors: Evan Kleiman; Alexander J Millner; Victoria W Joyce; Carol C Nash; Ralph J Buonopane; Matthew K Nock Journal: JMIR Mhealth Uhealth Date: 2019-09-24 Impact factor: 4.773